The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

摘要: Mutations in the epidermal growth factor receptor occur frequently a number of human tumours including gliomas, non-small-cell lung carcinomas, ovarian carcinomas and prostate carcinomas. The type III mutation (variously named EGFRvIII, de2-7 EGFR or AEGFR), which lacks portion extracellular ligand binding domain, is most common. Here, we review current status with regard to role EGFRvIII cancers. A detailed discussion formation its structure at protein level are likewise included along more functional roles. design use (preclinical clinical) small molecule inhibitors, antibodies, antisense oligonucleotides against wild-type considered detail as these strategies can be directly adapted target EGFRvIII. Finally, targeted therapy reviewed.